BioSpace News Archive

Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced that the Italian Medicines Agency, also known as Agenzia Italiana del Farmaco (AIFA), has enabled reimbursed access to Bylvay (odevixibat) for the treatment of all types of progressive familial intrahepatic cholestasis (PFIC) patients in Italy.

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that President and CEO Glenn Mattes will be participating in the H.C. Wainwright 24th Annual Global Investment Conference.

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference.

Biora Therapeutics, Inc. announced that the company’s management team will be presenting and participating in one-on-one meetings at the H.C. Wainwright 24th Annual Global Investment Conference, which is taking place both virtually and at the Lotte New York Palace Hotel in New York City, September 12-14, 2022.

Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of the management team will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022.

Emergent BioSolutions Inc. announced that it has dosed the first participant in its Phase 1 study evaluating the safety and immunogenicity of EBS-LASV, a recombinant VSV-vectored Lassa virus vaccine candidate being developed for prevention of disease caused by Lassa virus infection.

MannKind Corporation announced that it has successfully completed a Phase 1 study of clofazimine inhalation suspension and is planning discussions with the U.S. Food and Drug Administration regarding results and the ongoing clinical program.

Helius Medical Technologies, Inc. announced that Dane Andreeff, President and Chief Executive Officer, and Jeff Mathiesen, Chief Financial Officer, will present at two upcoming healthcare conferences as follows.

Zomedica Corp., a veterinary health company offering diagnostic and therapeutic products for equine and companion animals, is pleased to announce that the PulseVet system has been named the Official Shock Wave Therapy of the National Cutting Horse Association.

Merck, known as MSD outside the United States and Canada, announced that Robert M. Davis, chief executive officer and president, and Dr. Dean Li, president, Merck Research Laboratories, are scheduled to participate in a virtual fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, Sept. 12, 2022, at 2:15 p.m. EDT.